# First in Human Study of M1069 in Advanced Solid Tumors

> **NCT05198349** · PHASE1 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Metastatic or Locally Advanced Unresectable Solid Tumors

## Interventions

- **DRUG:** M1069

## Key facts

- **NCT ID:** NCT05198349
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-02
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-08-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Overarching portfolio-level review of the company's oncology pipeline resulted in early termination of the study. The study was not terminated due to safety.
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198349, "First in Human Study of M1069 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05198349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*